Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
At 3 and 12 months post-index, however, the 1.0 mg dosage formulation was the most common (53% and 67%, respectively), followed by 0.5 mg (39% and 29%, respectively)
Study strengths and limitations This study has certain strengths and limitations
Weight loss and blood sugar improvements may temporarily plateau or fluctuate during the adjustment period
The following side effects are rare, but they do require medical attention
Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT
US$ 20.89
US$ 24.58
US$ 26.26
US$ 28.34
